Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS. J Surg Oncol 2019 Jun;119(7):824-835
Date
02/10/2019Pubmed ID
30737793DOI
10.1002/jso.25401Scopus ID
2-s2.0-85061235303 (requires institutional sign-in at Scopus site) 12 CitationsAbstract
New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.
Author List
Istl AC, Ruck JM, Morris CD, Levin AS, Meyer CF, Johnston FMAuthor
Alexandra C. Istl MD, MPH Assistant Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Chemotherapy, AdjuvantHumans
Neoadjuvant Therapy
Randomized Controlled Trials as Topic
Sarcoma
Survival Rate